Actively Recruiting
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Led by Perspective Therapeutics · Updated on 2026-04-30
112
Participants Needed
7
Research Sites
369 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
CONDITIONS
Official Title
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older
- Satisfactory organ function based on lab tests
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Life expectancy greater than 3 months
- Progressive disease after standard therapy or no standard therapy available
- Positive [203Pb]Pb-PSV359 SPECT/CT scan showing uptake in at least one known tumor lesion
- Histological, pathological, or cytological confirmation of locally advanced or metastatic solid tumor malignancy
You will not qualify if you...
- Known allergy to the active drug or any ingredients
- Active second cancer
- Pregnant or breastfeeding
- Known brain metastases
- Active or uncontrolled infections needing antifungal or antibiotic treatment within 3 days before enrollment
- Medical conditions making the study unsafe
- Medical or social issues that might interfere with study participation or radiation safety
- History of severe allergic reaction to study drug components
- Major surgery within 21 days before treatment; must be recovered and stable
- Recent diagnosis (within 4 weeks) of deep vein thrombosis or pulmonary embolism
- Current alcohol or illicit drug abuse
- Receipt of live or attenuated vaccine within 7 days before enrollment
- Systemic anticancer therapy within 4 weeks before study treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Biogenix
Miami, Florida, United States, 33165
Actively Recruiting
2
University of Kentucky
Lexington, Kentucky, United States, 40536
Actively Recruiting
3
Saint Louis University
St Louis, Missouri, United States, 63110
Actively Recruiting
4
Nebraska Cancer Specialists
Omaha, Nebraska, United States, 68130
Actively Recruiting
5
Ohio State University
Columbus, Ohio, United States, 43221
Actively Recruiting
6
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15232
Actively Recruiting
7
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
C
ClinicalTrials at Perspectivetherapeutics
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here